Pre-science biology: the proposed cooperative R & D agreement with Huazhong Agricultural University will help to increase the company's product reserve.
Pre-Science Biology (688526) announced that through competitive negotiations with Huazhong Agricultural University, the company has obtained the cooperative research and development of three projects, including recombinant canine parvovirus VP2 live canine distemper virus vaccine and rabies inactivated vaccine (SAD-dOG strain). Now it intends to sign a joint development agreement with Huazhong Agricultural University, and the company needs to pay a total of 3.4 million yuan to Huazhong Agricultural University for the above three R & D projects. The technical achievements and intellectual property rights produced by the cooperative R & D project are jointly owned by the company and Huazhong Agricultural University. Through cooperative research and development, we can increase the company's product reserve and enhance the company's market competitiveness.
Dongxing Securities: give pre-science biological buy rating
2021-10-29 Dongxing Securities Co., Ltd. Cheng Shiyue, Meng Lin conducted research on pre-science biology and issued a research report "Q3 performance is not as expected, R & D advantage continues to strengthen". This report gives a buy rating to pre-science biology, and the current stock price is 25.50 yuan. Pre-science biology (688526) event: the company announced its three-quarter report in 2021 that the company achieved a total operating income of 776 million yuan in the first three quarters, an increase of 28.37% over the same period last year, a net profit of 386 million yuan, an increase of 20.69% over the same period last year, and a net cash inflow of 474 million yuan from operating activities, an increase of 32% over the same period last year.
2021-10-28西南证券股份有限公司徐卿对科前生物进行研究并发布了研究报告《养殖盈利能力或迎修复，非强免龙头长期向好》，本报告对科前生物给出买入评级，当前股价为25.07元。 科前生物(688526) 业绩总结：公司2021年前三季度实现营业收入7.8亿元，同比增长28.4%，实现归母净利润3.9亿元，同比增长20.7%。单三季度实现营业收入2.3亿元，同比变动-7.4%，归母净利润为99
Graphic pre-biology three-quarter report: net profit per quarter in the third quarter decreased by 27.10% compared with the same period last year.
According to the third quarterly report of pre-science biology 2021, the company's main income was 776 million yuan, up 28.37% from the same period last year; the net profit was 386 million yuan, up 20.69% from the same period last year; and deducting 376 million yuan from non-net profit, up 20.04% from the same period last year. In the third quarter of 2021, the company's main income in a single quarter was 231 million yuan, down 7.42% from the same period last year; the net profit in a single quarter was 99.7647 million yuan, down 27.1% from the same period last year The non-net profit in a single quarter was 97.9147 million yuan, down 26.21% from the same period last year; the debt ratio was 18.68%, and the investment income was 3.7665 million.
A picture to understand the 2021 report of pre-science biology.
Securities Star data Center News, pre-Science Biology 2021 reported that the company's main income was 545 million yuan, up 53.49% from the same period last year; the net profit was 286 million yuan, up 56.45% from the same period last year; deducting 279 million yuan from non-net profit, up 53.96% from the same period last year; debt ratio 14.03%, investment income 2.5633 million yuan, financial expenses-29.2556 million yuan, gross profit margin 81.69%. There are four new shareholders in this period. China China Construction Bank Corporation Co., Ltd.-Castrol Agricultural Industry Equity Securities Investment Fund holds 2.216913 million shares, accounting for the proportion of outstanding shares.